FDA approves Pfizer's TUKYSA as first-line maintenance treatment for HER2+ metastatic breast cancer
The FDA approved TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a chemotherapy-free maintenance treatment for adults with HER2-positive metastatic breast cancer. The approval was supported by data showing more than 50% improvement in median progression-free survival.
